Join
Login
Join
Login
"Where Everyone Has an MBA"
Tel: (612) 246-4616
Home
Financial Analysis
Companies
Industries
Glossary
About
Frequently Asked Questions
User Testimonials
Contact Us
Navigation
Home
Financial Analysis
Companies
Industries
Glossary
About
- Frequently Asked Questions
- User Testimonials
Contact Us
Mereo BioPharma Group plc - AD - SIC # 8731 - COMMERCIAL PHY_SICAL AND BIOLOGICAL RESEARCH
Ticker
Exchange
SIC #
Website
Latest Ticker
MREO
Nasdaq
8731
https://www.mereobiopharma.com/
Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:
Latest Headlines for Mereo BioPharma Group plc - AD
MEREO BIOPHARMA (MREO) Loses -12.74% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner
- Apr 12th, 2024 1:35 pm
Mereo BioPharma to Participate in Fireside Chat at the 23rd Annual Needham Virtual Healthcare Conference
- Apr 3rd, 2024 11:30 am
Mereo BioPharma Group PLC (MREO) Announces Full Year 2023 Financial Results
- Mar 27th, 2024 9:27 pm
Mereo BioPharma Reports Full Year 2023 Financial Results and Provides Corporate Update
- Mar 27th, 2024 8:01 pm
Mereo BioPharma to Participate in Fireside Chat at the Leerink Partners Global Biopharma Conference
- Mar 5th, 2024 12:30 pm
Ultragenyx (RARE) Q4 Loss Narrower Than Expected, Revenues Beat
- Feb 16th, 2024 12:53 pm
15 Top Performing European Stocks So Far in 2024
- Feb 16th, 2024 8:57 am
Ultragenyx's (RARE) Preliminary 2023 Revenues Disappoint
- Jan 8th, 2024 5:18 pm
Mereo BioPharma Provides Update on Pipeline Progress and Corporate Developments
- Jan 8th, 2024 12:00 pm
Hedge Funds Say These Penny Stocks Are Poised to Explode
- Dec 19th, 2023 4:21 pm
Ultragenyx (RARE) Q3 Earnings and Revenues Miss Estimates
- Nov 3rd, 2023 3:43 pm
Mereo BioPharma Reports on Recent Program Developments and Provides Financial Update
- Oct 23rd, 2023 8:01 pm
Ultragenyx and Mereo BioPharma Announce Interim Phase 2 Data from Phase 2/3 Orbit Study Demonstrating Setrusumab (UX143) Significantly Reduced Fracture Rates in Patients with Osteogenesis Imperfecta (OI)
- Oct 14th, 2023 8:30 pm
Ultragenyx to Present Setrusumab (UX143) Update at ASBMR 2023 Including New Data from Phase 2/3 Orbit Study in Osteogenesis Imperfecta (OI)
- Oct 9th, 2023 12:00 pm
Mereo BioPharma to Participate in Fireside Chat at the 2023 Cantor Global Healthcare Conference
- Sep 21st, 2023 11:00 am
Mereo BioPharma Reports Interim Financial Results for the Six Months Ended June 30, 2023 and Provides Corporate Update
- Sep 7th, 2023 11:30 am
BAKER BROS. ADVISORS LP Acquires Significant Stake in Mereo BioPharma Group PLC
- Aug 11th, 2023 3:04 am
Ultragenyx (RARE) Q2 Loss Wider Than Expected, Revenues Beat
- Aug 4th, 2023 12:12 pm
Ultragenyx (RARE) Doses First Patients in Bone Disease Studies
- Jul 7th, 2023 11:46 am
Ultragenyx Announces First Patients Dosed in Phase 3 Program Evaluating Setrusumab (UX143) for the Treatment of Osteogenesis Imperfecta (OI)
- Jul 6th, 2023 12:00 pm
Scroll